RetinAI Medical AG Collaborates with Novartis Pharma AG

RetinAI Medical AG Collaborates with Novartis Pharma AG

By Healthcare Tech Outlook | Thursday, December 24, 2020

RetinAI Medical AG has announced a multi-year agreement with Novartis Pharma AG to use RetinAI's IT solutions and artificial intelligence software.

FREMONT, CA: RetinAI Medical AG has announced a multi-year agreement with Novartis Pharma AG and use its IT solutions and artificial intelligence software to support various ophthalmology and digital health initiatives. The two firms have previously successfully collaborated on pilot projects in this field of the disease.

A multi-centre international clinical trial involving patients with neovascular age-related macular degeneration (nAMD) will endorse the first initiative under the current Master Agreement. (nAMD). The research is intended to investigate the impact of optical coherence tomography (OCT) image solutions on disease activity assessment by using Artificial Intelligence (AI). The research, involving more than 500 patients, will be performed in many clinical centers in various European countries and Canada.

For this research, RetinAI will include a data processing tool, RetinAI Discovery, its CE-marked web-based software platform, to process data at scale across imaging platforms and devices efficiently. Today, Discovery is used for some of the most common types of eye diseases by professionals to navigate imaging data, compute imaging biomarkers and monitor improvements over time. RetinAIs instruments also assist diagnostic analyses and clinical workflows as well as patient monitoring & adherence to care.

Dirk Sauer, Global Development Head of the Ophthalmology Franchise at Novartis Pharma AG, sees RetinAI as a strategic partner for advancing eye care through digital innovation, "With previous projects, RetinAIs services have enabled us to enhance and more efficiently structure retina scans and data collected from our clinical studies. Together with RetinAI, we are working on end-to-end solutions to generate swift and comprehensive disease insights to better treat patients and improve patient outcomes."

Dr Carlos Ciller, CEO of RetinAI, commented, "RetinAI is excited to expand and intensify our partnership with Novartis who is one of the top pharma companies in ophthalmology with deep competence, dedication and focus on digital innovation in eye care. We clearly see the value that RetinAI can bring to Novartis. Our Discovery platform and AI tools are enablers to increase efficiency in research and clinical studies and we expect they can also improve medications and treatments for patients. We believe using RetinAIs technologies to support patients treated with ophthalmic medications will provide enhanced disease insights and create opportunities for more precise treatments."

Weekly Brief